香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1237） 澄清公告 授出股份獎勵 茲提述中科生物控股有限公司（「本公司」）於二零二五年八月八日及二零二五年 十二月五日刊發的公告（「該等公告」）及本公司於二零二五年九月二十二日刊發 的通函（「通函」），內容有關根據股份獎勵計劃發行新股份及授出股份獎勵。本公 告所用詞彙與該等公告及通函所界定者具有相同涵義。 本公司謹此澄清，向承授人授出股份獎勵後，根據二零二五年股份獎勵計劃，計劃 授權限額及服務提供商分項限額項下可供日後授出的股份數目將為3,705股。 CHINA ENVIRONMENTAL TECHNOLOGY AND BIOENERGY HOLDINGS LIMITED 中科生物控股有限公司 中科生物控股有限公司 主席 謝清美 中國，漳平，二零二五年十二月十一日 於本公告日期，執行董事為謝清美女士及吳哲彥先生及獨立非執行董事為謝國興 先生、鄭冰倩女士及吳麗 ...

中科生物(01237)发布公告，公司根据2025年股份奖励计划的条款向11名承授人授出合共960万股奖励股 份，惟须待承授人接纳方可作实。授予承授人的每份股份奖励均代表于其归属日收取一股股份的权利。 ...

智通财经APP讯，中科生物(01237)发布公告，公司根据2025年股份奖励计划的条款向11名承授人授出合 共960万股奖励股份，惟须待承授人接纳方可作实。授予承授人的每份股份奖励均代表于其归属日收取 一股股份的权利。 ...

格隆汇12月5日丨中科生物(01237.HK)公告，于2025年12月1日，公司根据2025年股份奖励计划的条款向 11名承授人授出合共960万股奖励股份，惟须待承授人接纳方可作实。授予承授人的每份股份奖励均代 表于其归属日收取一股股份的权利。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 CHINA ENVIRONMENTAL TECHNOLOGY AND BIOENERGY HOLDINGS LIMITED （於開曼群島註冊成立的有限公司） 中科生物控股有限公司 | 授出日期： | 二零二五年十二月五日 | | --- | --- | | 承授人： | 本集團11名經選定僱員 | | 授出的股份獎勵數目： | 合共9,600,000份股份獎勵 | | 所授出股份獎勵的購買價： | 零 | | 股份於授出日期的收市價： | 每股股份0.52港元 | | 歸屬期： | 100% 的股份獎勵將於自授出日期起計第一個週年 | | | 之日歸屬。 | 惟董事會可全權酌情決定該等股份獎勵或其任何 部分應予歸屬。 1 表現目標： 授出的股份獎勵並無附帶表現目標。 薪酬委員會知悉，二零二五年股份獎勵計劃的目的 為就合資格參與者對本集團的貢獻為其提供保留 激勵或獎勵，吸引合適人才以促進本集團發展，並 使承 ...

Core Viewpoint - Ningxia Zhongke Biotechnology Co., Ltd. is currently undergoing a restructuring plan, which may lead to a significant downward adjustment in its stock price due to potential capital reserve increases and other factors [2][3]. Group 1: Stock Price Risks - The company has indicated that its stock price may experience a downward adjustment of approximately 30% following the implementation of the restructuring plan, based on the closing price on December 3, 2025 [2][3]. - The adjustment in stock price will depend on the relationship between the closing price on the capital reserve increase registration date and the average price of the newly issued shares [3]. Group 2: Restructuring Uncertainties - The company has been ruled by the court to terminate the restructuring process and enter the execution phase of the restructuring plan, which carries the risk of being declared bankrupt if the plan is not executed [4]. - If the company is declared bankrupt, it will undergo liquidation, and its stock may face delisting according to the Shanghai Stock Exchange listing rules [4]. Group 3: Additional Risks - There are risks associated with the pre-restructuring investment agreements that have been signed, which may be terminated or become unenforceable [5]. - Other companies under the same group, such as Ningxia Zhongke New Materials Co., Ltd. and Ningxia Xinhai Hengli International Trade Co., Ltd., are also facing similar restructuring challenges and potential bankruptcy risks [6].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中科生物控股有限公司 呈交日期: 2025年12月2日 本月底法定/註冊股本總額： HKD 100,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01237 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 96,037,051 | | 0 | | 96,037,051 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 96,037,051 | | 0 | | 96,037,05 ...

Core Viewpoint - The announcement indicates a significant change in the ownership structure of Ningxia Zhongke Biological Technology Co., Ltd. due to the execution of its restructuring plan, resulting in Hunan Xinhong Pharmaceutical Co., Ltd. becoming the controlling shareholder and Liu Xirong as the actual controller [1][3][5]. Group 1: Basic Situation of the Equity Change - The court has approved the restructuring plan for the company, leading to the termination of its restructuring process [2][3]. - The total share capital of the company will increase from 684,883,775 shares to 1,615,883,775 shares after a capital reserve conversion, with 931,000,000 shares being issued [3][51]. - Hunan Xinhong will hold 357,142,857 shares, representing 22.10% of the total share capital post-conversion, thus becoming the controlling shareholder [1][5]. Group 2: Changes in Shareholding Structure - Before the equity change, Shanghai Zhongneng held 200,000,000 shares (29.20% of total shares), which will decrease to 12.38% after the change [5][17]. - The actual controller will shift from Yu Jianming to Liu Xirong following the equity change [5][49]. Group 3: Subsequent Matters - Hunan Xinhong and Shanghai Zhongneng are required to prepare equity change reports as per regulations [5][6]. - The restructuring investment involves a cash payment of 400 million yuan for the shares acquired by Hunan Xinhong, with a lock-up period of 36 months [51][60].

Core Viewpoint - The announcement details the progress of the second judicial auction of shares held by the controlling shareholder of Ningxia Zhongke Biotechnology Co., Ltd., indicating that the shares have been auctioned and the outcome is pending further legal procedures [2][4]. Group 1: Shareholding and Auction Details - Shanghai Zhongneng Enterprise Development (Group) Co., Ltd. holds 200,000,000 shares of Ningxia Zhongke, accounting for 29.20% of the total share capital, with all shares pledged and frozen [2][3]. - The second judicial auction for the 200,000,000 shares took place from November 17 to November 18, 2025, on the JD Network Judicial Auction platform [4][5]. - The auction results indicate that the shares were successfully bid on, with the final transaction subject to the court's auction ruling [5][6]. Group 2: Future Steps and Uncertainties - Following the auction, there are still steps involving the payment of auction proceeds, legal execution procedures, and the transfer of share ownership, which introduces uncertainty regarding the final outcome [2][6]. - If the shares are fully transferred, Shanghai Zhongneng will no longer hold any shares in the company [2][6]. - The company will closely monitor the situation and fulfill its information disclosure obligations as required by relevant laws and regulations [2][6].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中科生物控股有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01237 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000 | HKD | | 0.5 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 200,000,000 | HKD | | 0.5 | HKD | | 100,000,000 | 本月底法定/註冊股本總額 ...